Idenix Pharmaceuticals, Inc. Company Profile
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.
News Articles
Idenix Loses First Phase Of Patent Dispute With Gilead Sciences
CAMBRIDGE, Mass. (TheStreet) -- Idenix Pharmaceuticals shares are weak Monday morning following the loss in the first phase of a hepatitis C patent dispute with Gilead Sciences . The U.S. Patent and...
Novartis restructures deal with Idenix Pharmaceuticals
USA-based Idenix Pharmaceuticals (Nasdaq: IDIX) says that Swiss drug major Novartis (NOVN: VX) has restructured its commercialization collaboration with the firm, with Idenix regaining worldwide right...
Idenix takes first round beating in Gilead patent challenge
Shares of Idenix Pharmaceuticals fell after the company lost a first round of a hepatitis C drug patent dispute with Gilead Sciences in the US. Idenix CEO Ronald Renaud tried to calm investors on a...
News Summary: FDA stops Idenix drug testing
SIDELINED: Hepatitis C drug developer Idenix Pharmaceuticals Inc. said Thursday that the Food and Drug Administration halted trials of its most advanced drug because of concerns about its effects on p...
Idenix falls as FDA halts testing of 2nd drug
Idenix Pharmaceuticals Inc. shares fell Monday after the company said the Food and Drug Administration is halting development of another one of its hepatitis C drugs.Idenix said the FDA is barring it...
Idenix, Janssen work on hepatitis C treatments
Janssen Pharmaceuticals and Idenix Pharmaceuticals are working together on clinical development of direct-acting antiviral co -More-
Idenix says FDA seeks more time to review hepatitis C drug
(Reuters) - Idenix Pharmaceuticals Inc said the U.S. health regulator had informed the company that it would need more time to conduct a safety review of Idenix's hepatitis C drug.
Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) raised $176 million through the sale of 22 million shares at $8 in a bumped-up follow-on underwritten by JPMorgan; Leerink; BofA Merrill Lynch; and William Bl...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
This is an extension study for patients who have previously completed Idenix Study NV-02B-003. This study is being conducted to compare the safety and effectiveness of treatment beyond 1...
Companies
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Ide...
Idenix is pursuing a disciplined business strategy that seeks to capitalize upon the diverse expertise of the company’s management team. While Idenix is focused on bringing its late-stage product ca...
Bionest Partners Inc. provides strategy consulting services exclusively for the life science industries to help pharmaceutical, biopharmaceutical, diagnostics, biotechnology, and...
More Information about "Idenix Pharmaceuticals, Inc." on BioPortfolio
We have published hundreds of Idenix Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Idenix Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Idenix Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Idenix Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Idenix Pharmaceuticals, Inc. Drugs and Medications on this site too.
